Russian security chief calls for cooperation on cyber threatsRussian Politics & Diplomacy May 24, 14:34
About half of Russian Navy warships to be armed with Kalibr cruise missiles by late 2020Military & Defense May 24, 14:31
Stalin’s grandson passes away at 75Society & Culture May 24, 14:26
Russia’s defense minister slams reports on chemical weapons in Syria as 'unreliable'Russian Politics & Diplomacy May 24, 14:11
Stoltenberg admits NATO has no proof of Russia supporting TalibanWorld May 24, 13:34
Russia’s fifth-generation fighter jets to start arriving for troops in 2019Military & Defense May 24, 13:23
We are wide awake, says Russian defense minister about US threat from spaceMilitary & Defense May 24, 13:02
Press review: Manchester terror attack's call to arms and US' push for Assad's ousterPress Review May 24, 13:00
Russian Navy to get seven advanced nuclear submarines by 2021Military & Defense May 24, 12:44
MOSCOW, December 23. /TASS/. An experimental Ebola vaccine proved to be highly protective against the deadly virus in a major trial in Guinea, the World Health Organization announced in a statement Friday.
"While these compelling results come too late for those who lost their lives during West Africa's Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless," said Dr Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation, who is also the study’s lead author.
The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11,841 people in Guinea during 2015. Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.
The vaccine was manufactured by Merck, Sharpe & Dohme (MSD).
According to the WHO, more than 11,000 people died during the 2014-2015 Ebola outbreak in West Africa. Most fatalities occurred in Liberia, Sierra-Leone and Guinea.